XDemics

What XDemics does

XDemics is a Caltech spinout biotechnology company developing and commercializing the High-Density Cell Respiration (HDCR) platform, a proprietary gas-permeable membrane technology combined with a precision geometric design that decouples oxygen transfer from nutrient delivery and enables mammalian cells to grow at densities 10-100X higher than conventional polystyrene cultureware. The company's product portfolio centers on Expansify™ cultureware (24-well and 1-well plates for research use), Profusion-Midi™ and Profusion-Max bioreactors for production-scale manufacturing (under development), and the Gigacell™ device for GMP-grade therapeutic manufacturing (planned 2026 release). The technology enables kLa oxygen transfer rates of 60-100/hour versus approximately 10.8 for conventional methods, and the company claims a 5-liter Profusion-Midi can replace a 250-liter vessel while maintaining identical geometry from research to production scale.

XDemics targets four primary customer segments: academic and life science research institutions, biopharmaceutical and cell & gene therapy developers, contract development and manufacturing organizations (CDMOs), and viral therapeutics developers. Its go-to-market combines a direct e-commerce channel (purchase.xdemics.com) with a North American distribution agreement signed in January 2026 with VWR, part of Avantor (NYSE: AVTR), which provides access to VWR's global e-commerce platform, digital catalogs, and field sales organization. Revenue today is driven by Expansify research-use product sales, supplemented by a grant-based Expansify Innovation Awards program offering up to $10,000 in pilot-study funding; future revenue is expected from Profusion bioreactors, the Gigacell GMP device, and strategic collaborations such as the multi-year partnership with Omios Biologics for oncolytic virus therapeutics production.

The company is incorporated in Delaware and headquartered in San Rafael, California, with biological testing laboratories at the Buck Institute for Research on Aging in Novato. It holds an exclusive worldwide license to foundational IP from the California Institute of Technology and City of Hope National Medical Center, and was issued U.S. Patent No. 12,606,784 on April 21, 2026 covering its core technology. XDemics is a private company backed by investments from Caltech, GKCC, and the Rothenberg Innovation Initiative, plus an NIH NCATS grant (5R42TR002798-03), with a team of approximately 18 employees led by CEO Christopher Thanos, PhD and CTO/co-founder Colin Cook, PhD.

Name

XDemics

Legal name

XDemics Corporation

Website

https://xdemics.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

XDemics is a Caltech spinout that develops and sells the HDCR platform and Expansify cultureware, gas-permeable membrane products enabling 10-100X higher cell densities for academic researchers, biopharmaceutical and cell/gene therapy developers, CDMOs, and viral therapeutics companies.

Ownership category

akta.pro rank

Product category

Cell Culture & Bioprocessing Equipment

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Surgical and Medical Instrument Manufacturing (339112), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish) (HLAAABAG)

akta.pro secondary industries

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Aseptic Processing, Fill-Finish & Sterile Manufacturing Tech (isolators, lyophilization interfaces) (HLAAAJAG)

Keywords

• Cell culture consumables
• Bioprocessing bioreactors
• HDCR oxygen transfer
• Cell expansion technology
• Permeable membrane cultureware

Headquarters

HQ city

Novato

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Expansify™ Cultureware Sales: Sale of HDCR-based cell culture products including 24-well plates and 1-well plates available in 1-packs and 10-packs. Products sold directly through company website and through VWR distribution channel.
2. Profusion™ Bioreactor Products (Future): Production-scale bioreactor products under development. Planned to generate revenue from GMP-grade therapeutic manufacturing equipment.
3. Innovation Awards Program: Grant-based program offering up to $10,000 in awards for pilot studies using Expansify products. Awards are reviewed on rolling first-come-first-served basis.

Pricing tiers

Go-to-market motion3 records

Distribution channels2 records

Marketing channels7 records

Core offering

XDemics manufactures and sells HDCR-based cell culture products, including Expansify respiring cultureware (24-well and 1-well plates) for laboratory research and Profusion bioreactors (Profusion-Midi 5L, Profusion-Max larger format) for production-scale cell and gene therapy manufacturing. The company's High-Density Cell Respiration (HDCR) platform uses a gas-permeable membrane with a proprietary geometric design to deliver 10-100X higher cell densities than conventional cultureware, with linear scalability from benchtop plates to 50L bioreactors under an exclusive license to Caltech and City of Hope IP.

Product overview

XDemics offers a unified platform centered on its High-Density Cell Respiration (HDCR™) technology, which combines a gas-permeable membrane with a proprietary geometric design to overcome oxygen delivery limitations in cell culture. The product portfolio consists of: (1) Expansify™ cultureware (24-well and 1-well plates) for research use, delivering lab-bench cell expansion with 10-100X higher densities; (2) Profusion-Midi™ and Profusion-Max bioreactors for production-scale manufacturing; and (3) Gigacell™ device for GMP-grade therapeutic manufacturing (under development). The HDCR platform enables linear scalability from 96-well plates to large bioreactors, supporting workflows from early discovery through commercial production of T cell, stem cell, and viral-based therapies.

Differentiator

Problem solved

Functional benefit

Products and services

• Expansify Cultureware Oxygen-permeable respiring cultureware (24-well and 1-well plates) that uses HDCR membrane architecture to deliver 10-100X higher cell densities than conventional polystyrene plates. Targets academic researchers, biopharma, CDMOs, and government labs performing cell-based assays, high-throughput screening, gene editing, and early-stage cell expansion for research use.
• Profusion-Midi Bioreactor A 5-liter HDCR-based bioreactor intended for GMP-grade production of cell and gene therapies that replaces a conventional 250-liter vessel, using the same geometry as the Expansify plate to enable linear scale-up. Designed for biopharmaceutical manufacturers, CDMOs, and cell and gene therapy developers.
• Profusion-Max Bioreactor Larger-format HDCR-based bioreactor in the Profusion product family, designed for industrial-scale production of cell and gene therapies. Currently under development.
• Gigacell Device A production device built on HDCR technology for manufacturing GMP-grade therapeutics such as cell and gene therapies. Under development and planned for release later in 2026.

Quantifiable outcome

• 10-100X higher cell densities compared to conventional culture systems
• +6 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• Omios BiologicscoreStrategic or Co-development Partner · 20 April 2026Multi-year strategic collaboration to optimize production of Omios' next-generation oncolytic virus (OV) therapeutics using XDemics' HDCR bioproduction platform. The partnership addresses historical limitations in the oncolytic virus field—tumor selectivity and insufficient viral yields. Collaboration projects 50% reduction in production costs, potentially making advanced OV therapies more accessible to broader patient populations. XDemics provides manufacturing scale while Omios delivers biomarker-guided targeting technology.
• VWR (part of Avantor, NYSE: AVTR)coreChannel Partner/ Reseller/ Distributor · 16 January 2026Sales, distribution, and marketing agreement making Expansify products available through VWR's global distribution infrastructure, digital catalogs, e-commerce platform, and field sales organization. VWR actively promotes products to academic institutions, biopharmaceutical companies, CDMOs, cell and gene therapy developers, and government research facilities. Agreement significantly expands product availability and market reach.
• California Institute of Technology (Caltech)coreTechnology or IntegrationExclusive worldwide license to intellectual property portfolio covering HDCR technology and Expansify platform. Co-owner of foundational invention with City of Hope. XDemics is a Caltech spinout.
• City of Hope National Medical CentercoreTechnology or IntegrationExclusive worldwide license to intellectual property portfolio. Co-owner of foundational invention with Caltech. XDemics co-founder Prof. Yuman Fong is faculty at City of Hope.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Corning Life Sciences: Corning is a dominant supplier of cell culture vessels, cultureware, and bioprocess products including the CellCube and HYPERStack systems. As XDemics' VP BD Forrest Roush previously led Corning's $200M cell culture P&L, Corning is the most directly comparable incumbent and the company's primary competitive threat in cultureware.
• Sartorius: Sartorius is a leading global supplier of bioreactors, cell culture media, and bioprocess technologies used in cell and gene therapy manufacturing. Competes head-to-head with XDemics' Profusion bioreactor line and serves overlapping CDMO and biopharma customers with established GMP-grade product portfolios.
• Cytiva (Danaher): Cytiva offers a comprehensive portfolio of bioreactors, single-use technologies, and cell therapy manufacturing platforms used across the biopharma and advanced therapy industries. Competes directly with XDemics' Profusion bioreactor platform for production-scale cell therapy manufacturing customers.
• Thermo Fisher Scientific: Thermo Fisher's Life Sciences Solutions segment supplies Gibco cell culture media, Nunc cultureware, and bioreactor systems spanning research-through-GMP cell therapy manufacturing. Competes with XDemics across both cultureware and bioreactor product lines with much larger scale and global reach.
• Lonza: Lonza is one of the world's largest CDMOs with deep cell and gene therapy manufacturing services and proprietary process technologies. Competes with XDemics both as a manufacturing platform provider and as a CDMO that could in-source or partner with XDemics' HDCR technology.

Direct peers

• Eppendorf: Eppendorf supplies bioreactors (e.g., BioFlo and DASbox) and cell culture consumables used in research and process development. Overlaps with XDemics' high-density cell culture and small-scale bioreactor offering, particularly in academic and bioprocess development settings.
• PBS Biotech: PBS Biotech develops single-use, high-density cell culture bioreactors targeting cell and gene therapy manufacturing. Closest direct peer to XDemics' Profusion platform with a similar focus on high cell density bioreactor systems for advanced therapy production.
• Miltenyi Biotec: Miltenyi Biotec supplies cell therapy manufacturing platforms, closed-system bioreactors (e.g., Prodigy), and cell processing equipment used in CAR-T and other advanced therapy workflows. Directly comparable to XDemics in targeting GMP-grade cell therapy manufacturing customers with integrated devices and consumables.
• STEMCELL Technologies: STEMCELL Technologies supplies cell culture media, reagents, and tools for stem cell research and cell therapy development. Overlaps with XDemics' Expansify cultureware in serving academic and bioprocess development customers focused on high-quality cell expansion.

Emerging players

• Terumo BCT: Terumo BCT provides cell processing and cell therapy manufacturing systems including the Quantum Cell Expansion System used in advanced therapy production. Directly comparable to XDemics in the GMP cell therapy manufacturing device category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@xdemics
• LinkedInlinkedin.com/company/xdemics-corporation

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about XDemics